Company intelligence / Profile preview

EyePoint Pharmaceuticals

Watertown, Massachusetts, USAeyepointpharma.com ↗

Ownership: Public · EYPT
Employees: ~165
Development stage: Phase 3

Overview

EyePoint’s lead candidate DURAVYU™ (formerly EYP‑1901) has shown positive safety and efficacy in Phase 1 and topline Phase 2 trials for wet AMD. The company expects to initiate pivotal Phase 3 trials in wet AMD in 2024. Its sustained-release platform has been validated with four FDA-approved products historically. DEXYCU® was approved for post-surgical inflammation but the company now focuses on retina indications.

Therapeutic areas: Ophthalmology
Modalities: sustained-release drug delivery systemssmall molecules (notably tyrosine kinase inhibitors)injectable implants
Industry: Biotech

Drug pipeline

6 assets

vorolanib

5 more assets in the full pipeline.

Request access →

Partnerships

Equinox Sciences/Betta Pharmaceuticals – exclusive license for vorolanib outside China/Macao/Hong Kong/TaiwanQinetiQ – strategic partner on porous silicon technologyAlimera Sciences – past partnership on Iluvien productHarrow Health – alliance related to DEXYCU commercialization

Beyond the preview

Go deeper on EyePoint Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EyePoint Pharmaceuticals.

Explore the full profile